Yazar "Tacyildiz, Nurdan" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Cross-sectional study: long term follow-up care for pediatric cancer survivors in a developing country, Turkey: current status, challenges, and future perspectives(Tubitak Scientific & Technical Research Council Turkey, 2020) Incesoy Ozdemir, Sonay; Tacyildiz, Nurdan; Varan, Ali; Kebudi, Rejin; Zulfikar, Bulent; Celkan, Tiraje; Olgun, NurAim: The main purpose of this study is to determine the current status of long-term follow-up (LTFU) for childhood cancer survivors and the challenges of LTFU for pediatric cancer survivors at pediatric oncology institutions in Turkey. Material and methods: A questionnaire was e-mailed to the directors of 33 pediatric oncology centers (POCs) registered in the Turkish Pediatric Oncology Group (TPOG). of these 33 active TPOG institutions, 21 participated in the study and returned their completed questionnaires. Results: Only 1 of the 21 participating centers had a separate LTFU clinic. The remaining centers provided LTFU care for childhood cancer survivors at the pediatric oncology outpatient clinic. of these centers, 17 (80.9%) reported difficulty in transition from the pediatric clinic to the adult clinic, 14 (66.6%) reported insufficient care providers, and 12 (57.1%) reported insufficient time and transportation problems. As neglected late effects, 16 (76.1%) centers reported psychosocial and getty job problems and 11 (52.3%) reported sexual and cognitive problems. None of the centers had their own LTFU guidelines for their daily LTFU practice. Conclusion: This study was the first to gain an overview of the needs of POCs and the gaps in survivorship services in Turkey. The results from this study will help to develop a national health care system and national guidelines for pediatric cancer survivors.Öğe Effect of sodium thiosulfate anhydrous on cisplatin-induced ototoxicity in pediatric cancers: Turkish compassionate use treatment protocol-Updated results(Lippincott Williams & Wilkins, 2024) Unal, Emel Cabi; Tacyildiz, Nurdan; Canpolat, Cengiz; Ataseven, Eda; Sivrice, Ayse Cigdem; Sevinir, Betul; Ates, Dilvin Celik[Abstarct Not Available]Öğe PEDMARK® REDUCED THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH HEPATOBLASTOMA, SEEN IN A TURKISH COMPASSIONATE USE TREATMENT PROTOCOL(Wiley, 2023) Cabi, Emel Unal; Tacyildiz, Nurdan; Ataseven, Eda; Sivrice, Ayse Cigdem; Sevinir, Betul; Brock, Penelope; Bhattacharya, Ananya[Abstarct Not Available]Öğe Prognostic Factors and a New Prognostic Index Model for Children and Adolescents with Hodgkin's Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation Study Group(Galenos Yayincilik, 2016) Kesik, Vural; Atas, Erman; Karakukcu, Musa; Aksoylar, Serap; Erbey, Fatih; Tacyildiz, Nurdan; Kupesiz, Alphan; Oniz, Haldun; Unal, Ekrem; Kansoy, Savas; Ozturk, Guluz; Elli, Murat; Kaya, Zuhre; Unal, Emel; Hazar, Volkan; Bengoa, Sebnem Yilmaz; Karasu, Gulsun; Atay, Didem; Dagdemir, Ayhan; Oren, Hale; Kocak, Ulker; Yesilipek, M. AkifObjective: The prognostic factors and a new childhood prognostic index after autologous hematopoietic stem cell transplantation (AHSCT) in patients with relapsed/refractory Hodgkin's lymphoma (HL) were evaluated. Materials and Methods: The prognostic factors of 61 patients who underwent AHSCT between January 1990 and December 2014 were evaluated. In addition, the Age-Adjusted International Prognostic Index and the Childhood International Prognostic Index (CIPI) were evaluated for their impact on prognosis. Results: The median age of the 61 patients was 14.8 years (minimum-maximum: 5-20 years) at the time of AHSCT. There were single relapses in 28 patients, >= 2 relapses in eight patients, and refractory disease in 25 patients. The chemosensitivity/chemorefractory ratio was 36/25. No pretransplant radiotherapy, no remission at the time of transplantation, posttransplant white blood cell count over 10x10(3)/mu L, posttransplant positron emission tomography positivity at day 100, and serum albumin of < 2.5 g/dL at diagnosis were correlated with progression-free survival. No remission at the time of transplantation, bone marrow positivity at diagnosis, and relapse after AHSCT were significant parameters for overall survival. Conclusion: The major factors affecting the progression-free and overall survival were clearly demonstrated. A CIPI that uses a lactate dehydrogenase level of 500 IU/L worked well for estimating the prognosis. We recommend AHSCT at first complete remission for relapsed cases, and it should also be taken into consideration for patients with high prognostic scores at diagnosis.